KR20140107507A - 신규 항 인간 ctgf 항체 - Google Patents

신규 항 인간 ctgf 항체 Download PDF

Info

Publication number
KR20140107507A
KR20140107507A KR1020147020039A KR20147020039A KR20140107507A KR 20140107507 A KR20140107507 A KR 20140107507A KR 1020147020039 A KR1020147020039 A KR 1020147020039A KR 20147020039 A KR20147020039 A KR 20147020039A KR 20140107507 A KR20140107507 A KR 20140107507A
Authority
KR
South Korea
Prior art keywords
antibody
ser
human
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147020039A
Other languages
English (en)
Korean (ko)
Inventor
쇼지 이와사키
류이치 모리야
마사야스 요시노
고지 다카쿠라
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20140107507A publication Critical patent/KR20140107507A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147020039A 2011-12-22 2012-12-21 신규 항 인간 ctgf 항체 Abandoned KR20140107507A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2011-281811 2011-12-22
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトｃｔｇｆ抗体

Publications (1)

Publication Number Publication Date
KR20140107507A true KR20140107507A (ko) 2014-09-04

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020039A Abandoned KR20140107507A (ko) 2011-12-22 2012-12-21 신규 항 인간 ctgf 항체

Country Status (16)

Country Link
US (1) US9587015B2 (enExample)
EP (1) EP2796550B1 (enExample)
JP (1) JP6040943B2 (enExample)
KR (1) KR20140107507A (enExample)
CN (1) CN104011206B (enExample)
AR (1) AR089425A1 (enExample)
BR (1) BR112014015405A2 (enExample)
CA (1) CA2859627A1 (enExample)
EA (1) EA029290B1 (enExample)
ES (1) ES2665851T3 (enExample)
IN (1) IN2014CN04615A (enExample)
MX (1) MX345019B (enExample)
PL (1) PL2796550T3 (enExample)
PT (1) PT2796550T (enExample)
TW (1) TW201333034A (enExample)
WO (1) WO2013094723A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
CA3142092A1 (en) * 2019-06-04 2020-12-10 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof
US20230416352A1 (en) * 2020-12-03 2023-12-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JPWO2023238845A1 (enExample) 2022-06-07 2023-12-14
AU2023373601A1 (en) 2022-10-31 2025-04-03 Astellas Pharma Inc. Antibody-drug conjugate containing a toll-like receptor 7/8 dual agonist compound
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用
WO2025047848A1 (ja) 2023-08-30 2025-03-06 アステラス製薬株式会社 ＩｄｅＺ改変体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
DE69433422T2 (de) 1993-03-11 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Monoklonaler anti-hiv antikörper
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
MXPA01005949A (es) 1998-12-14 2002-09-18 Univ Miami Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
PL2796550T3 (pl) 2018-08-31
CN104011206B (zh) 2017-03-08
MX2014007681A (es) 2014-11-25
EA201491240A1 (ru) 2014-11-28
JP6040943B2 (ja) 2016-12-07
BR112014015405A2 (pt) 2017-06-13
EP2796550A4 (en) 2015-08-19
WO2013094723A1 (ja) 2013-06-27
TW201333034A (zh) 2013-08-16
MX345019B (es) 2017-01-11
JPWO2013094723A1 (ja) 2015-04-27
AR089425A1 (es) 2014-08-20
EA029290B1 (ru) 2018-03-30
US9587015B2 (en) 2017-03-07
EP2796550B1 (en) 2018-02-28
CN104011206A (zh) 2014-08-27
PT2796550T (pt) 2018-04-18
IN2014CN04615A (enExample) 2015-09-18
ES2665851T3 (es) 2018-04-27
US20140343258A1 (en) 2014-11-20
EP2796550A1 (en) 2014-10-29
CA2859627A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US20230056881A1 (en) TARGETED TGFß INHIBITION
KR102536014B1 (ko) Pd-1 효능제 항체 및 그의 용도
KR102897330B1 (ko) 항-pd-1 항체 및 조성물
KR101439719B1 (ko) Ｃｓｆ-１ｒ에 대한 항체
KR101919170B1 (ko) 중화 항-ccl20 항체
KR102216088B1 (ko) 다중특이성 항체, 다중특이성 활성화 가능한 항체 및 그의 사용 방법
JP4432031B2 (ja) インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
CN1780855B (zh) 人IL-1β拮抗剂
KR101585990B1 (ko) 암 치료를 위한 ｃｌａｕｄｉｎ-18에 대한 모노클로날 항체
CN101928345B (zh) 一种人源化抗体及其人源化改造方法
KR20190008955A (ko) 항 cd47 단일클론항체 및 그 용도
KR20180133198A (ko) T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN111303293B (zh) 一种融合蛋白及其用途
CN110144008B (zh) Cd38蛋白抗体及其应用
KR20140032392A (ko) 신규 항 인간 ｉｌ-23 수용체 항체
CN103588878A (zh) 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
US20250376533A1 (en) Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof
KR102903323B1 (ko) 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
KR20230150858A (ko) Il-6 수용체 및 혈관신생 인자를 표적화하는 항체 융합 단백질
RU2858169C2 (ru) Слитые белки антитела, нацеленные на рецептор IL-6 и ангиогенные факторы
RU2776795C2 (ru) Антитела к белку cd38 и их применение
RU2788128C2 (ru) Антитела к лиганду рецепторной тирозинкиназы 3, подобной продукту протоонкогена вируса саркомы кошек (fms) штамма mcdonough (flt3l), и варианты их применения для лечения аутоиммунных и воспалительных заболеваний
KR20240115840A (ko) 인간화 항dnam-1 항체
HK40006534B (zh) Cd38蛋白抗体及其应用
HK40006534A (en) Cd38 protein antibody and its application

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190117

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190621

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee